Industry / Japan
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Mylan Announces Generic Sector Assault
March 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Another drugmaker has outlined an aggressive strategy to penetrate Japan's booming generic drug sector, confirming the trend that has emerged over the last six months. US-based Mylan Laboratories will launch new products for the treatment of neurological disorders, introduce advanced formulation technologies and supply rivals with cheap raw ingredients. Given the sector's attractive growth rates, BMI expects other major generic drugmakers - such as Switzerland's Sandoz and US firm Barr Laboratories - to increase their footprint in Japan.